Search

Author/Creator Hedenfalk, Ingrid

1. Assessment of early response biomarkers in relation to long‐term survival in patients with HER2‐negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. Issue 3 (13th October 2017)

Authors:
Kimbung, Siker; Markholm, Ida; Bjöhle, Judith; Lekberg, Tobias; von Wachenfeldt, Anna; Azavedo, Edward; Saracco, Ariel; Hellström, Mats; Veerla, Srinivas; Paquet, Eric; Bendahl, Pär‐Ola; Fernö, Mårten; Bergh, Jonas; Loman, Niklas; Hatschek, Thomas; Hedenfalk, Ingrid
Journal:
International journal of cancer
Issue:
Volume 142:Issue 3(2018)
Page Start:
618
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Common Susceptibility Loci for Male Breast Cancer. (12th August 2020)

Authors:
Maguire, Sarah; Perraki, Eleni; Tomczyk, Katarzyna; Jones, Michael E; Fletcher, Olivia; Pugh, Matthew; Winter, Timothy; Thompson, Kyle; Cooke, Rosie; Trainer, Alison; James, Paul; Bojesen, Stig; Flyger, Henrik; Nevanlinna, Heli; Mattson, Johanna; Friedman, Eitan; Laitman, Yael; Palli, Domenico; M...
Journal:
Journal of the National Cancer Institute
Issue:
Volume 113:Number 4(2021)
Page Start:
453
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. (2nd September 2018)

Authors:
Matikas, Alexios; Lövrot, John; Ramberg, Anna; Eriksson, Margareta; Lindsten, Therese; Lekberg, Tobias; Hedenfalk, Ingrid; Loman, Niklas; Bergh, Jonas; Hatschek, Thomas; Erlandsson, Ann; Foukakis, Theodoros
Journal:
Oncoimmunology
Issue:
Volume 7:Number 9(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Genome methylation patterns in male breast cancer – Identification of an epitype with hypermethylation of polycomb target genes. Issue 8 (8th May 2015)

Authors:
Johansson, Ida; Lauss, Martin; Holm, Karolina; Staaf, Johan; Nilsson, Cecilia; Fjällskog, Marie-Louise; Ringnér, Markus; Hedenfalk, Ingrid
Journal:
Molecular oncology
Issue:
Volume 9:Issue 8(2015:Oct.)
Page Start:
1565
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers. (2021)

Authors:
Haugen, Mads H.; Lingjærde, Ole Christian; Hedenfalk, Ingrid; Garred, Øystein; Borgen, Elin; Loman, Niklas; Hatschek, Thomas; Børresen-Dale, Anne-Lise; Naume, Bjørn; Mills, Gordon B.; Mælandsmo, Gunhild M.; Engebraaten, Olav
Journal:
JCO precision oncology
Issue:
Volume 5(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery. (1st November 2020)

Authors:
Bååth, Maria; Westbom-Fremer, Sofia; Martin de la Fuente, Laura; Ebbesson, Anna; Davis, Juliette; Malander, Susanne; Måsbäck, Anna; Kannisto, Päivi; Hedenfalk, Ingrid
Journal:
Molecular & cellular oncology
Issue:
Volume 7:Number 6(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗